How big is Ironwood Pharmaceuticals, Inc.?

As of Jun 18, Ironwood Pharmaceuticals, Inc. has a market capitalization of 102.69 million and net sales of 317.68 million, with a net profit of -31.41 million over the latest four quarters. Shareholder's funds are at -301.33 million, and total assets are 350.91 million as of Dec 24.

As of Jun 18, Ironwood Pharmaceuticals, Inc. has a market capitalization of 102.69 million, categorizing it as a Small Cap company.<BR><BR>As of Jun 18, the sum of net sales for the latest four quarters is 317.68 million, while the sum of net profit for the same period is -31.41 million.<BR><BR>As of Dec 24, the reporting period shows shareholder's funds at -301.33 million and total assets at 350.91 million.

What does Ironwood Pharmaceuticals, Inc. do?

Ironwood Pharmaceuticals, Inc. is a biotechnology company focused on developing products for unmet medical needs. As of March 2025, it reported net sales of $41 million and a net loss of $37 million, with a market cap of $102.69 million.

Overview:<BR>Ironwood Pharmaceuticals, Inc. is a biotechnology company operating in the Pharmaceuticals & Biotechnology industry, focusing on advancing product opportunities in areas of unmet medical need.<BR><BR>Financial Snapshot:<BR>- Most recent Net Sales: 41 Million (Quarterly Results - Mar 2025)<BR>- Most recent Net Profit: -37 Million (Quarterly Results - Mar 2025)<BR>- Market cap: USD 102.69 Million (Small Cap)<BR><BR>Key Metrics:<BR>- P/E: NA (Loss Making)<BR>- Industry P/E: NA<BR>- Dividend Yield: 0.00%<BR>- Debt Equity: -1.43<BR>- Return on Equity: 2.69%<BR>- Price to Book: -0.31<BR><BR>Contact Details:<BR>- Address: 100 Summer St Ste 2300, BOSTON MA: 02110-2156<BR>- Tel: ['1 617 6217722', '1 617 3745082']<BR>- Fax: 1 617 4940480<BR>- Website: http://www.ironwoodpharma.com/

Should I buy, sell or hold Ironwood Pharmaceuticals, Inc.?

Who are in the management team of Ironwood Pharmaceuticals, Inc.?

As of March 2022, the management team of Ironwood Pharmaceuticals, Inc. includes Ms. Julie McHugh (Independent Chairman), Mr. Mark Mallon (CEO), and several directors: Dr. Mark Currie, Dr. Alexander Denner, Mr. Andrew Dreyfus, Mr. Jon Duane, and Ms. Marla Kessler. They oversee the company's strategic direction and operations.

As of March 2022, the management team of Ironwood Pharmaceuticals, Inc. includes the following individuals:<BR><BR>- Ms. Julie McHugh, Independent Chairman of the Board<BR>- Mr. Mark Mallon, Chief Executive Officer and Director<BR>- Dr. Mark Currie, Director<BR>- Dr. Alexander Denner, Director<BR>- Mr. Andrew Dreyfus, Independent Director<BR>- Mr. Jon Duane, Independent Director<BR>- Ms. Marla Kessler, Independent Director<BR><BR>This team is responsible for overseeing the company's strategic direction and operations.

Is Ironwood Pharmaceuticals, Inc. overvalued or undervalued?

As of August 8, 2023, Ironwood Pharmaceuticals is considered overvalued and risky, with a negative price-to-book value of -0.29, an EV to EBITDA ratio of 6.72, and a year-to-date return of -67.04%, significantly underperforming the S&P 500's 12.22%.

As of 8 August 2023, the valuation grade for Ironwood Pharmaceuticals, Inc. has moved from expensive to risky, indicating a shift towards a more cautious outlook. The company appears to be overvalued given its negative price-to-book value of -0.29, an EV to EBITDA ratio of 6.72, and a high ROCE of 57.96%, which may not be sustainable in the long term. In comparison, a peer like Ironwood has a P/E ratio of 13.855, suggesting that the market may be pricing other companies in the industry more favorably.<BR><BR>The stock has experienced significant underperformance compared to the S&P 500, with a year-to-date return of -67.04% versus the S&P 500's 12.22%. This stark contrast reinforces the notion that Ironwood Pharmaceuticals is currently overvalued in the market.

Is Ironwood Pharmaceuticals, Inc. technically bullish or bearish?

As of June 13, 2025, Ironwood Pharmaceuticals has shifted to a mildly bearish trend, with mixed technical indicators and significant underperformance compared to the S&P 500, showing a year-to-date return of -67.04%.

As of 13 June 2025, the technical trend for Ironwood Pharmaceuticals, Inc. has changed from bearish to mildly bearish. The current stance is mildly bearish overall. Key indicators include a mildly bullish MACD on both weekly and monthly time frames, a bullish RSI on the monthly, and a mildly bearish daily moving average. However, the Bollinger Bands show a bullish weekly but a mildly bearish monthly trend, and the KST indicates a bullish weekly but bearish monthly stance. The Dow Theory supports a mildly bullish view on both weekly and monthly time frames. <BR><BR>In terms of multi-period returns, the stock has significantly underperformed compared to the S&P 500, with a year-to-date return of -67.04% versus 12.22% for the index, and a one-year return of -67.70% compared to 17.14%.